68
Participants
Start Date
November 30, 2008
Primary Completion Date
November 30, 2008
Study Completion Date
November 30, 2008
Irinotecan
Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
Capecitabine
Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
Cetuximab
Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
Oxaliplatin
Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
University Hospital of Heraklion, Dep of Medical Oncology, Heraklion
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli
"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens
401 Military Hospital of Athens, Athens
Air Forces Military Hospital of Athens, Athens
"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens
State General Hospital of Larissa, Larissa
"Metaxa's Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology", Piraeus
"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki
Interbalkan Hospital, division of Oncology, Pylaia, Thessaloniki, Thessaloniki
Lead Sponsor
University Hospital of Crete
OTHER
Hellenic Oncology Research Group
OTHER